- Trial phase
- Approved
- Time to market
- Already approved and commercialized (FDA approved December 2021)
- Why 3/10
- Apretude is already FDA-approved and commercialized with no pending PDUFA or pivotal readout in the next ~12 months. It is one of many products in a large, diversified pharma company (GSK), so even strong sales growth or competitive news for this single drug would drive only a modest move in GSK's share price. Per the rubric, an approved drug with no imminent binary catalyst scores 3-5; 3 is appropriate given low concentration relative to GSK's total pipeline.
Apretude is a commercial-stage asset with no near-term binary regulatory catalyst. Watch for quarterly ViiV sales disclosures within GSK's earnings, competitive threat from Gilead's evolving long-acting PrEP pipeline (e.g., lenacapavir), and any label-expansion updates. For GSK investors, Apretude is a growth contributor but not a standalone thesis driver.
Price Chart
Executive Summary
Apretude (cabotegravir extended-release injectable) is the first and only long-acting injectable option for HIV pre-exposure prophylaxis (PrEP), developed by ViiV Healthcare (majority-owned by GSK). FDA-approved in December 2021, it offers every-2-month dosing vs. daily oral pills like Truvada/Descovy. Real-world data shows >99% effectiveness and zero HIV acquisitions in implementation studies. However, as an already-approved, marketed product within a large diversified pharma company, there is no imminent binary catalyst to move GSK's stock meaningfully on this drug alone. GSK's consensus analyst rating is 'hold' with a mean price target of ~$58 (8.5% implied upside from ~$51.60).
How It Works
Cabotegravir is an integrase strand transfer inhibitor (INSTI), it blocks an enzyme HIV needs to replicate. Apretude is formulated as a long-acting injection that releases the drug slowly over months, so patients receive a starting dose, another dose one month later, and then an injection every two months to maintain protection against HIV infection.
Trial Status
Apretude received FDA approval in December 2021 based on two pivotal Phase 3 trials (HPTN 083 and HPTN 084) showing superior efficacy to daily oral TDF/FTC in cisgender men/transgender women who have sex with men (p=0.0003) and in cisgender women (p<0.0001). Multiple real-world implementation studies presented at IDWeek 2024 and CROI 2025 demonstrate >99% effectiveness with zero HIV acquisitions in varied clinical settings.
The Two-Sided Case
Upcoming Catalysts
- Quarterly GSK earnings reports with ViiV/Apretude sales disclosures
- Potential FDA or EMA label expansions (e.g., broader age groups or dosing intervals)
- Competitive landscape updates from Gilead's lenacapavir PrEP program
- Pricing/reimbursement decisions in additional countries
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GSK plc 6-K GSK ·Originating report